Covid19

🔴 Variants of SARS-CoV-2

🔵 The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology

🔴 Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome

PE in COVID-19 patients at ED presentation is unusual (about 0.5%), but incidence is approximately 9 fold higher than in the general (non-COVID-19) population. Moreover, risk factors and leg symptoms are less frequent, D-dimer increase is lower and emboli involve smaller pulmonary arteries. While PE probably does not increase the mortality of COVID-19 patients, mortality is higher in COVID-19 than in non-COVID-19 patients with PE.

🔴 Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination - Mix * Match vaccines

🔵 Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

heterologous vector/mRNA boosting induces strong humoral and cellular immune responses with acceptable reactogenicity profiles.